{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003005","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.837360+00:00","generated_at":"2026-05-17T11:15:06.107867+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt","bullets":["Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.","Cash used in operations $8.4M; cash and equivalents $1.2M at Dec 31, 2024.","Auditor emphasizes substantial doubt about going concern due to recurring losses.","Total liabilities $6.9M exceed assets $2.9M; capital deficiency of $4.0M.","Financial statements retroactively adjusted for 1-for-15 reverse split effective July 28, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003005","json":"https://secwatch.observer/filing/0001178913-25-003005.json","markdown":"https://secwatch.observer/filing/0001178913-25-003005.md","text":"https://secwatch.observer/filing/0001178913-25-003005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/0001178913-25-003005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/zk2533676.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:15:06.107867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}